LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829).

Authors :: Cho, B.C.
Ahn, M-J.
Kang, J.H.
Soo, R.
Baisamut (Reungwetwattana), T.
Yang, J.C-H.
Cicin, I.
Kim, D-W.
Wu, Y-L.
Lu, S.
Lee, K.
Pang, Y-K.
Zimina, A.
Fong, C.H.
Poddubskaya, E.
Kim, Y.
An, T.
Lee, H.
Byun, H.
Zaric, B.
Source :: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1560-S1560. 1p.
Publication Year :: 2022

Subjects :: *EPIDERMAL growth factor receptors
*GEFITINIB
*NON-small-cell lung carcinoma
*THERAPEUTICS
*SAFETY

Full Text Access

Tools